(Q37760210)

22 August 2017

1 reference

title

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies (English)

1 reference

22 August 2017

1 reference

peripheral neuropathy

1 reference

Guido Cavaletti

1

0 references

Andrzej Jakubowiak

series ordinal

2

object named as

Andrzej J Jakubowiak

1 reference

22 August 2017

publication date

1 July 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

51

1 reference

22 August 2017

issue

7

1 reference

22 August 2017

page(s)

1178-1187

1 reference

A phase 2 study of bortezomib in relapsed, refractory myeloma

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Topical analgesic combinations for bortezomib neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Immune-mediated neuropathies in myeloma patients treated with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Induction of angiogenesis by normal and malignant plasma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Antimyeloma activity of heat shock protein-90 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Heat shock proteins and protection of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Bortezomib: a novel chemotherapeutic agent for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.483303

10.3109/10428194.2010.483303

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference